Debopam Samanta
Concepts (310)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Epilepsy | 22 | 2023 | 192 | 12.870 |
Why?
| Seizures | 18 | 2023 | 201 | 5.110 |
Why?
| Spasms, Infantile | 8 | 2022 | 31 | 4.130 |
Why?
| Anticonvulsants | 12 | 2023 | 137 | 4.090 |
Why?
| Cannabidiol | 5 | 2022 | 35 | 3.960 |
Why?
| Status Epilepticus | 6 | 2021 | 38 | 3.800 |
Why?
| Tuberous Sclerosis | 6 | 2022 | 37 | 3.750 |
Why?
| Mutation | 15 | 2022 | 1437 | 3.180 |
Why?
| Electroencephalography | 17 | 2022 | 366 | 2.570 |
Why?
| Epilepsies, Myoclonic | 4 | 2020 | 11 | 2.550 |
Why?
| Humans | 95 | 2023 | 54858 | 2.340 |
Why?
| Hemiplegia | 3 | 2021 | 11 | 2.330 |
Why?
| Intellectual Disability | 4 | 2019 | 146 | 2.280 |
Why?
| Brain | 9 | 2019 | 1436 | 2.170 |
Why?
| Child | 32 | 2023 | 7280 | 1.970 |
Why?
| Developmental Disabilities | 5 | 2019 | 126 | 1.940 |
Why?
| Epilepsy, Absence | 3 | 2019 | 12 | 1.890 |
Why?
| Magnetic Resonance Imaging | 15 | 2019 | 1699 | 1.710 |
Why?
| Neuroaxonal Dystrophies | 2 | 2022 | 9 | 1.610 |
Why?
| Nervous System Malformations | 3 | 2020 | 17 | 1.600 |
Why?
| Folate Receptor 1 | 2 | 2022 | 24 | 1.570 |
Why?
| Epilepsies, Partial | 2 | 2022 | 13 | 1.470 |
Why?
| Infant, Newborn, Diseases | 2 | 2020 | 65 | 1.450 |
Why?
| Ketamine | 2 | 2020 | 61 | 1.450 |
Why?
| Neurocutaneous Syndromes | 2 | 2019 | 7 | 1.320 |
Why?
| Cadherins | 2 | 2019 | 80 | 1.280 |
Why?
| Infant | 16 | 2022 | 3798 | 1.270 |
Why?
| Cerebral Arteries | 2 | 2019 | 36 | 1.210 |
Why?
| Sirolimus | 2 | 2017 | 65 | 1.170 |
Why?
| Child, Preschool | 16 | 2021 | 4179 | 1.150 |
Why?
| Angiofibroma | 2 | 2015 | 6 | 1.140 |
Why?
| Facial Neoplasms | 2 | 2015 | 24 | 1.110 |
Why?
| Valproic Acid | 2 | 2022 | 33 | 1.090 |
Why?
| Nerve Tissue Proteins | 2 | 2018 | 213 | 1.090 |
Why?
| Pregnanolone | 2 | 2023 | 6 | 1.000 |
Why?
| Stroke | 3 | 2019 | 548 | 1.000 |
Why?
| Epilepsy, Generalized | 1 | 2023 | 10 | 0.950 |
Why?
| Landau-Kleffner Syndrome | 1 | 2022 | 3 | 0.940 |
Why?
| Male | 32 | 2021 | 28269 | 0.920 |
Why?
| Aphasia | 1 | 2022 | 24 | 0.910 |
Why?
| Female | 28 | 2023 | 29374 | 0.900 |
Why?
| Quality Improvement | 2 | 2022 | 240 | 0.880 |
Why?
| Nervous System Diseases | 2 | 2021 | 100 | 0.860 |
Why?
| Chromosome Deletion | 3 | 2019 | 156 | 0.850 |
Why?
| Emergencies | 1 | 2021 | 95 | 0.820 |
Why?
| Transition to Adult Care | 1 | 2020 | 13 | 0.810 |
Why?
| Angelman Syndrome | 1 | 2020 | 2 | 0.800 |
Why?
| Pharmaceutical Preparations | 1 | 2021 | 90 | 0.800 |
Why?
| Treatment Outcome | 8 | 2023 | 5803 | 0.790 |
Why?
| Immunoglobulins, Intravenous | 1 | 2021 | 52 | 0.780 |
Why?
| Fenfluramine | 1 | 2020 | 7 | 0.780 |
Why?
| Oligonucleotides, Antisense | 1 | 2020 | 31 | 0.770 |
Why?
| Phenobarbital | 1 | 2020 | 19 | 0.770 |
Why?
| Dioxolanes | 1 | 2020 | 13 | 0.760 |
Why?
| Flunarizine | 1 | 2019 | 1 | 0.760 |
Why?
| Behavioral Symptoms | 1 | 2019 | 6 | 0.760 |
Why?
| Excitatory Amino Acid Antagonists | 1 | 2020 | 50 | 0.750 |
Why?
| Ocular Physiological Phenomena | 1 | 2019 | 5 | 0.740 |
Why?
| Tetrasomy | 1 | 2019 | 2 | 0.740 |
Why?
| Agenesis of Corpus Callosum | 2 | 2018 | 9 | 0.740 |
Why?
| Immunologic Factors | 1 | 2021 | 136 | 0.740 |
Why?
| Chromosomes, Human, Pair 5 | 1 | 2019 | 16 | 0.740 |
Why?
| Sneddon Syndrome | 1 | 2019 | 3 | 0.740 |
Why?
| Livedo Reticularis | 1 | 2019 | 5 | 0.730 |
Why?
| Oral Ulcer | 1 | 2019 | 3 | 0.730 |
Why?
| Behcet Syndrome | 1 | 2019 | 7 | 0.730 |
Why?
| Calcium Channel Blockers | 1 | 2019 | 73 | 0.720 |
Why?
| Transposases | 1 | 2019 | 10 | 0.720 |
Why?
| Andersen Syndrome | 1 | 2019 | 1 | 0.720 |
Why?
| Genetic Therapy | 1 | 2020 | 115 | 0.720 |
Why?
| Hydrocephalus | 1 | 2019 | 41 | 0.720 |
Why?
| Vitiligo | 1 | 2019 | 8 | 0.710 |
Why?
| Receptors, GABA-B | 1 | 2019 | 13 | 0.710 |
Why?
| Spinal Cord Diseases | 1 | 2019 | 39 | 0.710 |
Why?
| Nephrotic Syndrome | 2 | 2017 | 22 | 0.710 |
Why?
| Autoimmune Diseases of the Nervous System | 1 | 2019 | 10 | 0.710 |
Why?
| Cytochrome-c Oxidase Deficiency | 1 | 2018 | 3 | 0.710 |
Why?
| Leukoencephalopathies | 1 | 2019 | 17 | 0.710 |
Why?
| Migraine Disorders | 2 | 2020 | 50 | 0.700 |
Why?
| Optic Atrophy | 1 | 2018 | 11 | 0.700 |
Why?
| Cannabinoid Receptor Agonists | 1 | 2019 | 45 | 0.700 |
Why?
| Cerebral Infarction | 1 | 2018 | 30 | 0.700 |
Why?
| Muscle Weakness | 1 | 2019 | 46 | 0.700 |
Why?
| Electron Transport Complex IV | 1 | 2018 | 35 | 0.690 |
Why?
| Diffuse Cerebral Sclerosis of Schilder | 1 | 2018 | 8 | 0.690 |
Why?
| Amino Acyl-tRNA Synthetases | 1 | 2018 | 6 | 0.690 |
Why?
| Edema | 1 | 2019 | 71 | 0.690 |
Why?
| Shab Potassium Channels | 1 | 2018 | 2 | 0.690 |
Why?
| Photic Stimulation | 1 | 2018 | 67 | 0.690 |
Why?
| Brain Edema | 1 | 2018 | 40 | 0.670 |
Why?
| Alopecia | 1 | 2019 | 62 | 0.670 |
Why?
| Physicians | 1 | 2022 | 253 | 0.670 |
Why?
| Parents | 1 | 2021 | 352 | 0.660 |
Why?
| Lymphohistiocytosis, Hemophagocytic | 1 | 2018 | 29 | 0.660 |
Why?
| Tumor Suppressor Proteins | 2 | 2016 | 144 | 0.660 |
Why?
| Myoclonus | 1 | 2018 | 11 | 0.660 |
Why?
| Biomedical Research | 1 | 2021 | 247 | 0.660 |
Why?
| Artifacts | 1 | 2018 | 62 | 0.660 |
Why?
| Thrombocytopenia | 1 | 2019 | 101 | 0.660 |
Why?
| Mitochondrial Diseases | 1 | 2018 | 47 | 0.650 |
Why?
| Autoimmune Diseases | 1 | 2019 | 114 | 0.650 |
Why?
| Neurodegenerative Diseases | 1 | 2018 | 85 | 0.640 |
Why?
| Abnormalities, Multiple | 2 | 2019 | 166 | 0.630 |
Why?
| Practice Guidelines as Topic | 1 | 2020 | 505 | 0.630 |
Why?
| Osteochondrodysplasias | 1 | 2017 | 15 | 0.630 |
Why?
| Hearing Loss, Sensorineural | 1 | 2018 | 78 | 0.630 |
Why?
| Immunologic Deficiency Syndromes | 1 | 2017 | 21 | 0.620 |
Why?
| Arteriosclerosis | 1 | 2017 | 61 | 0.620 |
Why?
| Carotid Artery Diseases | 1 | 2017 | 39 | 0.610 |
Why?
| Child Development | 1 | 2018 | 213 | 0.600 |
Why?
| Drug Discovery | 1 | 2017 | 95 | 0.600 |
Why?
| Cafe-au-Lait Spots | 1 | 2016 | 2 | 0.590 |
Why?
| Phenotype | 2 | 2021 | 844 | 0.590 |
Why?
| Prenatal Exposure Delayed Effects | 1 | 2018 | 201 | 0.590 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 570 | 0.590 |
Why?
| Erythema Infectiosum | 1 | 2015 | 3 | 0.580 |
Why?
| Leukoencephalitis, Acute Hemorrhagic | 1 | 2015 | 3 | 0.580 |
Why?
| Migraine with Aura | 1 | 2015 | 5 | 0.580 |
Why?
| Williams Syndrome | 1 | 2016 | 29 | 0.580 |
Why?
| Models, Biological | 1 | 2020 | 857 | 0.580 |
Why?
| Sinus Pericranii | 1 | 2015 | 1 | 0.580 |
Why?
| Parvovirus B19, Human | 1 | 2015 | 17 | 0.570 |
Why?
| SOS1 Protein | 1 | 2015 | 2 | 0.570 |
Why?
| Crying | 1 | 2015 | 4 | 0.570 |
Why?
| Toes | 1 | 2015 | 20 | 0.570 |
Why?
| Electrodiagnosis | 1 | 2015 | 15 | 0.570 |
Why?
| Moyamoya Disease | 1 | 2015 | 7 | 0.570 |
Why?
| Iatrogenic Disease | 1 | 2015 | 26 | 0.570 |
Why?
| Hyperventilation | 1 | 2015 | 8 | 0.570 |
Why?
| Tuberculoma | 1 | 2015 | 3 | 0.560 |
Why?
| Epilepsy, Benign Neonatal | 1 | 2015 | 3 | 0.560 |
Why?
| Adolescent | 12 | 2023 | 7022 | 0.560 |
Why?
| Infant, Newborn | 5 | 2020 | 2890 | 0.560 |
Why?
| Noonan Syndrome | 1 | 2015 | 12 | 0.560 |
Why?
| Pulmonary Embolism | 1 | 2017 | 113 | 0.560 |
Why?
| Neurologic Examination | 1 | 2015 | 75 | 0.550 |
Why?
| Skin | 1 | 2019 | 470 | 0.550 |
Why?
| Mutism | 1 | 2015 | 3 | 0.550 |
Why?
| NAV1.2 Voltage-Gated Sodium Channel | 1 | 2015 | 3 | 0.550 |
Why?
| Encephalitis | 1 | 2016 | 49 | 0.550 |
Why?
| Ocular Motility Disorders | 1 | 2015 | 24 | 0.550 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2015 | 89 | 0.540 |
Why?
| Communication | 3 | 2022 | 273 | 0.540 |
Why?
| Bone Diseases, Developmental | 1 | 2014 | 13 | 0.540 |
Why?
| Tooth Abnormalities | 1 | 2014 | 11 | 0.540 |
Why?
| Trisomy | 1 | 2014 | 36 | 0.530 |
Why?
| Energy Drinks | 1 | 2014 | 7 | 0.520 |
Why?
| KCNQ2 Potassium Channel | 1 | 2014 | 17 | 0.520 |
Why?
| Neurology | 1 | 2015 | 44 | 0.520 |
Why?
| Corpus Callosum | 1 | 2014 | 26 | 0.520 |
Why?
| Diagnosis, Differential | 7 | 2020 | 1179 | 0.510 |
Why?
| Vasoconstriction | 1 | 2014 | 60 | 0.510 |
Why?
| Syndrome | 5 | 2020 | 260 | 0.510 |
Why?
| Osteomyelitis | 1 | 2015 | 123 | 0.510 |
Why?
| Benzodiazepines | 1 | 2014 | 73 | 0.510 |
Why?
| Influenza, Human | 1 | 2015 | 125 | 0.500 |
Why?
| Membrane Proteins | 1 | 2016 | 387 | 0.480 |
Why?
| Repressor Proteins | 1 | 2014 | 172 | 0.470 |
Why?
| Sleep | 1 | 2014 | 198 | 0.470 |
Why?
| Enzyme Inhibitors | 1 | 2015 | 455 | 0.460 |
Why?
| Magnetic Resonance Angiography | 3 | 2019 | 83 | 0.450 |
Why?
| Immunosuppressive Agents | 3 | 2019 | 257 | 0.430 |
Why?
| Pediatrics | 1 | 2015 | 308 | 0.410 |
Why?
| Quality of Life | 3 | 2022 | 905 | 0.400 |
Why?
| Receptors, N-Methyl-D-Aspartate | 2 | 2022 | 119 | 0.390 |
Why?
| Diffusion Magnetic Resonance Imaging | 3 | 2017 | 132 | 0.390 |
Why?
| Caregivers | 2 | 2021 | 242 | 0.350 |
Why?
| Recurrence | 3 | 2019 | 701 | 0.350 |
Why?
| Echinocandins | 1 | 2008 | 66 | 0.340 |
Why?
| Mycoses | 1 | 2008 | 157 | 0.320 |
Why?
| Gastroesophageal Reflux | 2 | 2019 | 52 | 0.310 |
Why?
| Administration, Topical | 2 | 2015 | 72 | 0.280 |
Why?
| Antifungal Agents | 1 | 2008 | 361 | 0.280 |
Why?
| Retrospective Studies | 5 | 2023 | 6462 | 0.240 |
Why?
| Speech Disorders | 1 | 2022 | 19 | 0.230 |
Why?
| Ethosuximide | 1 | 2022 | 5 | 0.230 |
Why?
| Clonazepam | 1 | 2022 | 5 | 0.230 |
Why?
| Electrodes, Implanted | 1 | 2022 | 27 | 0.230 |
Why?
| Stereotaxic Techniques | 1 | 2022 | 36 | 0.230 |
Why?
| Cluster Analysis | 1 | 2023 | 260 | 0.220 |
Why?
| Death, Sudden | 1 | 2022 | 18 | 0.220 |
Why?
| GTPase-Activating Proteins | 1 | 2022 | 24 | 0.220 |
Why?
| Concept Formation | 1 | 2021 | 12 | 0.220 |
Why?
| Freedom | 1 | 2021 | 3 | 0.220 |
Why?
| Perivascular Epithelioid Cell Neoplasms | 1 | 2021 | 5 | 0.220 |
Why?
| Diazepam | 1 | 2021 | 23 | 0.210 |
Why?
| Folic Acid | 1 | 2022 | 135 | 0.210 |
Why?
| Drug Interactions | 1 | 2022 | 211 | 0.210 |
Why?
| Fibroma | 1 | 2021 | 42 | 0.210 |
Why?
| Adrenocorticotropic Hormone | 2 | 2022 | 36 | 0.200 |
Why?
| Dihydroergotamine | 1 | 2020 | 5 | 0.200 |
Why?
| Personal Satisfaction | 1 | 2021 | 93 | 0.200 |
Why?
| Brain Diseases | 1 | 2021 | 87 | 0.200 |
Why?
| Soft Tissue Neoplasms | 1 | 2021 | 68 | 0.200 |
Why?
| Diet Therapy | 1 | 2020 | 9 | 0.190 |
Why?
| Risk Factors | 2 | 2020 | 4082 | 0.190 |
Why?
| Perception | 1 | 2021 | 150 | 0.190 |
Why?
| Genetic Diseases, Inborn | 1 | 2020 | 26 | 0.190 |
Why?
| Qualitative Research | 1 | 2021 | 336 | 0.190 |
Why?
| Consensus | 1 | 2021 | 155 | 0.190 |
Why?
| Ubiquitin-Protein Ligases | 1 | 2020 | 103 | 0.190 |
Why?
| Anesthetics | 1 | 2020 | 38 | 0.190 |
Why?
| Clinical Protocols | 1 | 2020 | 124 | 0.190 |
Why?
| Treatment Failure | 1 | 2020 | 144 | 0.190 |
Why?
| Leukomalacia, Periventricular | 1 | 2019 | 13 | 0.190 |
Why?
| Matrix Attachment Region Binding Proteins | 1 | 2020 | 31 | 0.190 |
Why?
| Muscle Hypotonia | 1 | 2019 | 22 | 0.190 |
Why?
| Chromosomes, Human, Pair 7 | 1 | 2019 | 31 | 0.180 |
Why?
| HLA-B51 Antigen | 1 | 2019 | 2 | 0.180 |
Why?
| Ventriculoperitoneal Shunt | 1 | 2019 | 27 | 0.180 |
Why?
| Learning | 1 | 2021 | 172 | 0.180 |
Why?
| Craniofacial Abnormalities | 1 | 2019 | 29 | 0.180 |
Why?
| Patient-Centered Care | 1 | 2021 | 133 | 0.180 |
Why?
| Potassium Channels, Inwardly Rectifying | 1 | 2019 | 6 | 0.180 |
Why?
| Ventricular Premature Complexes | 1 | 2019 | 6 | 0.180 |
Why?
| Heart Septal Defects, Atrial | 1 | 2019 | 46 | 0.180 |
Why?
| Analgesics, Non-Narcotic | 1 | 2020 | 146 | 0.180 |
Why?
| Melkersson-Rosenthal Syndrome | 1 | 2018 | 4 | 0.180 |
Why?
| Microcephaly | 1 | 2019 | 43 | 0.180 |
Why?
| Facial Nerve Diseases | 1 | 2018 | 6 | 0.180 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2022 | 577 | 0.180 |
Why?
| Disease Management | 1 | 2020 | 198 | 0.170 |
Why?
| Nocturnal Myoclonus Syndrome | 1 | 2018 | 14 | 0.170 |
Why?
| Facial Paralysis | 1 | 2018 | 20 | 0.170 |
Why?
| Syncope | 1 | 2019 | 35 | 0.170 |
Why?
| Cerebral Veins | 1 | 2018 | 17 | 0.170 |
Why?
| Referral and Consultation | 1 | 2021 | 316 | 0.170 |
Why?
| Deglutition Disorders | 1 | 2019 | 74 | 0.170 |
Why?
| Anti-Arrhythmia Agents | 1 | 2019 | 96 | 0.170 |
Why?
| Frameshift Mutation | 1 | 2018 | 18 | 0.170 |
Why?
| Health Personnel | 1 | 2021 | 250 | 0.170 |
Why?
| Video Recording | 1 | 2018 | 94 | 0.170 |
Why?
| Acute Disease | 1 | 2019 | 416 | 0.170 |
Why?
| Fatal Outcome | 1 | 2019 | 232 | 0.170 |
Why?
| Fear | 1 | 2018 | 94 | 0.160 |
Why?
| Fibrinolytic Agents | 1 | 2019 | 153 | 0.160 |
Why?
| Adult | 4 | 2023 | 14634 | 0.160 |
Why?
| Combined Modality Therapy | 1 | 2020 | 697 | 0.160 |
Why?
| India | 1 | 2017 | 82 | 0.160 |
Why?
| Clinical Trials as Topic | 1 | 2020 | 503 | 0.160 |
Why?
| Anti-Inflammatory Agents | 1 | 2019 | 189 | 0.160 |
Why?
| History, 21st Century | 1 | 2017 | 66 | 0.160 |
Why?
| Cerebellum | 1 | 2018 | 147 | 0.160 |
Why?
| Neurotoxicity Syndromes | 1 | 2017 | 51 | 0.160 |
Why?
| Methotrexate | 1 | 2017 | 78 | 0.160 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2019 | 204 | 0.160 |
Why?
| History, 20th Century | 1 | 2017 | 124 | 0.160 |
Why?
| Anti-Infective Agents | 1 | 2017 | 111 | 0.150 |
Why?
| Pandemics | 1 | 2021 | 565 | 0.150 |
Why?
| Aldehyde Dehydrogenase | 1 | 2016 | 28 | 0.150 |
Why?
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 103 | 0.150 |
Why?
| Influenza B virus | 1 | 2015 | 6 | 0.150 |
Why?
| Hormones | 1 | 2016 | 63 | 0.140 |
Why?
| Delayed Diagnosis | 1 | 2016 | 26 | 0.140 |
Why?
| Chromosomes, Human, Pair 3 | 1 | 2015 | 20 | 0.140 |
Why?
| Transcription Factors | 1 | 2020 | 646 | 0.140 |
Why?
| North America | 1 | 2015 | 74 | 0.140 |
Why?
| Animals | 3 | 2022 | 14855 | 0.140 |
Why?
| Arkansas | 1 | 2021 | 2231 | 0.140 |
Why?
| Facies | 1 | 2014 | 35 | 0.130 |
Why?
| Cerebral Angiography | 1 | 2015 | 108 | 0.130 |
Why?
| Chromosomes, Human, Pair 9 | 1 | 2014 | 24 | 0.130 |
Why?
| Brain Waves | 1 | 2014 | 23 | 0.130 |
Why?
| Antibiotics, Antineoplastic | 1 | 2015 | 85 | 0.130 |
Why?
| Complementary Therapies | 1 | 2015 | 33 | 0.130 |
Why?
| Drug Resistance | 1 | 2015 | 76 | 0.130 |
Why?
| Antiemetics | 1 | 2014 | 33 | 0.130 |
Why?
| Headache | 1 | 2014 | 81 | 0.130 |
Why?
| Vomiting | 1 | 2014 | 77 | 0.120 |
Why?
| Mutation, Missense | 1 | 2014 | 116 | 0.120 |
Why?
| Glutamine | 1 | 2015 | 168 | 0.120 |
Why?
| Polymerase Chain Reaction | 1 | 2015 | 555 | 0.120 |
Why?
| Decision Making, Computer-Assisted | 1 | 2013 | 5 | 0.120 |
Why?
| Arginine | 1 | 2015 | 184 | 0.120 |
Why?
| Analgesics | 1 | 2014 | 111 | 0.120 |
Why?
| Vigabatrin | 2 | 2022 | 2 | 0.110 |
Why?
| Diagnostic Errors | 1 | 2013 | 76 | 0.110 |
Why?
| Evidence-Based Medicine | 1 | 2013 | 291 | 0.110 |
Why?
| Inflammation | 1 | 2016 | 704 | 0.100 |
Why?
| Pregnancy | 1 | 2018 | 2691 | 0.100 |
Why?
| Signal Transduction | 1 | 2017 | 1855 | 0.090 |
Why?
| Dysentery | 1 | 2009 | 1 | 0.090 |
Why?
| Trichuriasis | 1 | 2009 | 1 | 0.090 |
Why?
| Trichuris | 1 | 2009 | 1 | 0.090 |
Why?
| Anesthesia, Intravenous | 1 | 2008 | 13 | 0.090 |
Why?
| Eosinophils | 1 | 2009 | 37 | 0.090 |
Why?
| Antineoplastic Agents | 1 | 2017 | 1299 | 0.090 |
Why?
| Lipopeptides | 1 | 2008 | 66 | 0.080 |
Why?
| Amyloidosis | 1 | 2009 | 82 | 0.080 |
Why?
| Inflammatory Bowel Diseases | 1 | 2009 | 56 | 0.080 |
Why?
| Tuberculosis | 1 | 2009 | 120 | 0.080 |
Why?
| Candidiasis | 1 | 2008 | 122 | 0.080 |
Why?
| Aspergillosis | 1 | 2008 | 133 | 0.080 |
Why?
| Prospective Studies | 2 | 2023 | 2623 | 0.070 |
Why?
| Kidney Diseases | 1 | 2009 | 303 | 0.070 |
Why?
| Potassium Channels | 1 | 2021 | 40 | 0.050 |
Why?
| Administration, Intravenous | 1 | 2020 | 82 | 0.050 |
Why?
| Sleep Stages | 1 | 2020 | 47 | 0.050 |
Why?
| Age of Onset | 1 | 2020 | 122 | 0.050 |
Why?
| Cognition | 1 | 2022 | 356 | 0.050 |
Why?
| Immunohistochemistry | 1 | 2021 | 1123 | 0.040 |
Why?
| Software | 1 | 2013 | 280 | 0.020 |
Why?
| Internet | 1 | 2013 | 301 | 0.020 |
Why?
| Young Adult | 1 | 2020 | 4437 | 0.020 |
Why?
| Antinematodal Agents | 1 | 2009 | 3 | 0.020 |
Why?
| Mebendazole | 1 | 2009 | 3 | 0.020 |
Why?
| Leukemoid Reaction | 1 | 2009 | 8 | 0.020 |
Why?
| Antitubercular Agents | 1 | 2009 | 95 | 0.020 |
Why?
| Colonoscopy | 1 | 2009 | 111 | 0.020 |
Why?
| Prognosis | 1 | 2009 | 2139 | 0.010 |
Why?
|
|
Samanta's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|